Pharmaceutical Technology
JANUARY 21, 2024
CDMOs, who cater to the requirements of multiple companies and develop platform processes to achieve the much-needed economy of scale, are being seen as a possible solution.
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 21, 2024
With a fatality rate 20 times that of COVID-19, and no vaccine, Disease X could swiftly bring humanity to its knees. Few would be left untouched by the pathogen were it to gain hold, causing healthcare systems to crumble and economies to collapse as the world once again tried to contain a force of nature.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 21, 2024
Bristol-Myers Squibb’s Opdivo-Yervoy regimen improves PFS as first-line therapy for patients with MSI-H/dMMR colorectal cancer in CheckMate-8HW trial
Drug Patent Watch
JANUARY 21, 2024
Annual Drug Patent Expirations for RHOFADE Rhofade is a drug marketed by Mayne Pharma and is included in one NDA. It is available from one supplier. There are eight patents… The post New patent expiration for Mayne Pharma drug RHOFADE appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
JANUARY 21, 2024
A vote by the HELP committee in the US on 31st January could result in the CEOs of Johnson & Johnson and Merck being forced to testify on drug pricing
Drug Discovery World
JANUARY 21, 2024
SLAS2024 International Conference and Exhibition takes place in Boston, USA, on 3-7 February. DDW will be hosting two conference tracks highlighting expertise in the lab to patient process. In a new feature for SLAS2024, DDW will be hosting a programme of presentations at the Ignite Theater located in the exhibition hall on 5 and 6 February: ‘Innovation & technology: from lab to patient’.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Roots Analysis
JANUARY 21, 2024
With fourteen approved drugs and several drug candidates being evaluated under different stages of development, antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics. The success of this relatively novel class of therapeutics is attributed to the ability of lead molecules to specifically identify and eliminate disease associated cells / pathogens, consequently, addressing most of the concerns related to off target toxicities.
Drug Patent Watch
JANUARY 21, 2024
This chart shows the companies which have received the most New Patient Population exclusivities in the past five years. New Patient Populations are one of the categories for which the… The post Pharmaceutical companies with the most ‘New Patient Population’ drugs appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
246 
Let's personalize your content